SCHEMBL2943271

SCHEMBL2943271

N[C@@H]1CCCC[C@H]1Sc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 2/20 0.39
GRM2 Q14416 2/20 0.39
GRM3 Q14832 2/20 0.39
F2 P00734 2/20 0.37
PRSS1 P07477 2/20 0.37
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MAOA P21397 8/20 0.34
MAOB P27338 8/20 0.34
KDM1A O60341 5/20 0.34
CYP2C19 P33261 4/20 0.34
CYP2B6 P20813 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 2/20 0.34
TAAR1 Q96RJ0 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1541019 1.00 GRM6 (0.39) GRM6GRM2GRM3F2PRSS1
SCHEMBL1540260 1.00 GRM6 (0.39) GRM6GRM2GRM3F2PRSS1
SCHEMBL2943267 1.00 GRM6 (0.39) GRM6GRM2GRM3F2PRSS1
SCHEMBL2943272 1.00 GRM6 (0.39) GRM6GRM2GRM3F2PRSS1
SCHEMBL1540203 0.96 F2 (0.40) GRM6GRM2GRM3F2PRSS1
SCHEMBL576029 0.76 MAOA (0.53) F2PRSS1DDB1CRBNKMT2A
SCHEMBL1540258 0.76 F2 (0.40) GRM6GRM2GRM3F2PRSS1
SCHEMBL21029448 0.76 KMT2A (0.38) GRM6GRM2GRM3F2PRSS1
SCHEMBL9847802 0.76 TSHR (0.50) GRM6GRM2GRM3F2PRSS1
SCHEMBL775766 0.76 F2 (0.37) GRM6GRM2GRM3F2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 GRM6 3476/4885GRM2 4093/4885GRM3 4491/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 GRM6 3626/4885GRM2 4178/4885GRM3 4497/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 GRM6 3476/4885GRM2 4093/4885GRM3 4491/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR GRM6 3595/4885GRM2 4268/4885GRM3 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.